Dinalbuphine sebacate - Lumosa Therapeutics

Drug Profile

Dinalbuphine sebacate - Lumosa Therapeutics

Alternative Names: LT 1001; Naldebain; SDE; Sebocoyl dinalbuphine ester

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lumosa Therapeutics
  • Class Analgesics; Esters; Ethers; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 28 Aug 2017 Lumosa Therapeutics and Camargo Pharmaceutical Services agree to co-develop dinalbuphine sebacate in USA for Pain
  • 03 Aug 2017 Dinalbuphine sebacate is still in phase-II/III development for Pain in Taiwan (Lumosa Therapeutics website, August 2017)
  • 03 Aug 2017 Dinalbuphine sebacate is available for licensing as of 03 Aug 2017. www.lumosa.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top